Haojie Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haojie Xu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Libo Zhao
Clinical Research Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
3 shared publications - Mengmeng Liu
Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
3 shared publications - Yongbo Chen
Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
2 shared publications - Guoqing Liu
Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
1 shared publication - Jiachen Tu
Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
1 shared publication - Jueyu Li
Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
1 shared publication
Latest Publications
- Open Access
- 20 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1190
Narrow Therapeutic Index Drugs: Regulatory Frameworks, Bioequivalence, and Model-Informed Precision Dosing
Background/Objectives: Narrow therapeutic index (NTI) drugs are characterized by a small margin between effective and toxic exposure. This review aimed to summarize international definitions and regulatory frameworks for NTI drugs, compare bioequivalence requirements for generic NTI products, and evaluate the role of model-informed approaches in precision dosing and lifecycle risk management. Methods: A structured literature search was conducted in PubMed, MEDLINE, Embase, Web of Science, Scopus, and the China National Knowledge Infrastructure from database inception to 30 June 2026. Official documents from major regulatory authorities were also reviewed. Evidence relating to NTI drug classification, bioequivalence, interchangeability, therapeutic drug monitoring, population pharmacokinetics, physiologically based pharmacokinetics, machine learning, and hybrid modeling was included. Results: Definitions, drug lists, study designs, and bioequivalence criteria varied substantially across jurisdictions. Several authorities use narrowed acceptance ranges, whereas China and the United States apply fully replicated crossover designs with reference-scaled average bioequivalence, average bioequivalence constraints, and within-subject variability comparisons for selected NTI drugs. Population pharmacokinetic and Bayesian approaches remain the most mature tools for therapeutic drug monitoring and individualized dosing. Physiologically based models support drug–drug interaction prediction, special-population extrapolation, virtual bioequivalence, and clinically relevant formulation specifications. Machine-learning and hybrid models improve exposure, dose, and toxicity-risk prediction, but most evidence remains retrospective and externally limited. Conclusions: NTI drug regulation and clinical management remain heterogeneous. Greater international harmonization, standardized model validation, prospective clinical evaluation, and integration of regulatory, formulation, and patient-level data are needed to support safer substitution and more reliable precision dosing.
- 20 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1190
Open AccessNarrow Therapeutic Index Drugs: Regulatory Frameworks, Bioequivalence, and Model-Informed Precision Dosing
Background/Objectives: Narrow therapeutic index (NTI) drugs are characterized by a small margin between effective and toxic exposure. This review aimed to summarize international definitions and regulatory frameworks for NTI drugs, compare bioequivalence requirements for generic NTI products, and evaluate the role of model-informed approaches in precision dosing and lifecycle risk management. Methods: A structured literature search was conducted in PubMed, MEDLINE, Embase, Web of Science, Scopus, and the China National Knowledge Infrastructure from database inception to 30 June 2026. Official documents from major regulatory authorities were also reviewed. Evidence relating to NTI drug classification, bioequivalence, interchangeability, therapeutic drug monitoring, population pharmacokinetics, physiologically based pharmacokinetics, machine learning, and hybrid modeling was included. Results: Definitions, drug lists, study designs, and bioequivalence criteria varied substantially across jurisdictions. Several authorities use narrowed acceptance ranges, whereas China and the United States apply fully replicated crossover designs with reference-scaled average bioequivalence, average bioequivalence constraints, and within-subject variability comparisons for selected NTI drugs. Population pharmacokinetic and Bayesian approaches remain the most mature tools for therapeutic drug monitoring and individualized dosing. Physiologically based models support drug–drug interaction prediction, special-population extrapolation, virtual bioequivalence, and clinically relevant formulation specifications. Machine-learning and hybrid models improve exposure, dose, and toxicity-risk prediction, but most evidence remains retrospective and externally limited. Conclusions: NTI drug regulation and clinical management remain heterogeneous. Greater international harmonization, standardized model validation, prospective clinical evaluation, and integration of regulatory, formulation, and patient-level data are needed to support safer substitution and more reliable precision dosing.
- Open Access
- 20 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 1030
Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization
Background: Prophylaxis in children with hemophilia B (HB) lacks quantitative approaches that integrate both plasma exposure and tissue distribution. This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model of factor IX (FIX) for pediatric HB. The model incorporated the binding of FIX to type IV collagen (Col4) to characterize its distribution in both plasma and extravascular tissues. Methods: A total of 20 children with severe HB were included, contributing 219 plasma samples. The base PBPK model was first established and verified using adult and plasma-derived FIX (pdFIX) data. It was subsequently extrapolated to children by integrating FIX-CTBB parameters and pediatric observations for model calibration. The validated model was used to characterize plasma pharmacokinetics, predict tissue distribution and target attainment, and simulate alternative prophylactic dosing regimens. Results: The model adequately described the plasma pharmacokinetics of FIX in children and predicted substantial extravascular distribution. Total extravascular exposure was approximately sixfold higher than plasma exposure. Marked heterogeneity in target attainment was identified across tissues. Lower target attainment was observed in the colon, pancreas, and brain, whereas delayed attainment occurred in bone and muscle. Simulations of prophylactic dosing regimens suggested that 75 IU/kg twice weekly may provide a favorable balance among sustained FIX exposure, tissue-level target attainment, and treatment burden. Conclusions: This PBPK model provides a mechanistic and quantitative framework for characterizing plasma and tissue exposure to FIX in children with HB and may support individualized optimization of FIX prophylactic dosing.
- 20 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 1030
Open AccessPhysiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization
Background: Prophylaxis in children with hemophilia B (HB) lacks quantitative approaches that integrate both plasma exposure and tissue distribution. This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model of factor IX (FIX) for pediatric HB. The model incorporated the binding of FIX to type IV collagen (Col4) to characterize its distribution in both plasma and extravascular tissues. Methods: A total of 20 children with severe HB were included, contributing 219 plasma samples. The base PBPK model was first established and verified using adult and plasma-derived FIX (pdFIX) data. It was subsequently extrapolated to children by integrating FIX-CTBB parameters and pediatric observations for model calibration. The validated model was used to characterize plasma pharmacokinetics, predict tissue distribution and target attainment, and simulate alternative prophylactic dosing regimens. Results: The model adequately described the plasma pharmacokinetics of FIX in children and predicted substantial extravascular distribution. Total extravascular exposure was approximately sixfold higher than plasma exposure. Marked heterogeneity in target attainment was identified across tissues. Lower target attainment was observed in the colon, pancreas, and brain, whereas delayed attainment occurred in bone and muscle. Simulations of prophylactic dosing regimens suggested that 75 IU/kg twice weekly may provide a favorable balance among sustained FIX exposure, tissue-level target attainment, and treatment burden. Conclusions: This PBPK model provides a mechanistic and quantitative framework for characterizing plasma and tissue exposure to FIX in children with HB and may support individualized optimization of FIX prophylactic dosing.
- Open Access
- 24 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1149
Global Prevalence of Asthma in Adults with Atopic Dermatitis and the Atopic Dermatitis–Asthma Association
Background: Atopic dermatitis (AD) and asthma are common type 2 inflammatory diseases linked by the atopic march. In adults with AD, the prevalence of comorbid asthma and the strength of the AD–asthma association remain uncertain, with marked heterogeneity across studies. Moreover, the role of modern systemic therapies in this comorbidity is increasingly debated. Objective: To estimate the global pooled prevalence of asthma in adults with AD, quantify the AD–asthma association, and discuss the potential impact of targeted therapies (dupilumab, abrocitinib, omalizumab) on asthma comorbidity. Methods: Systematic review and random-effects meta-analysis (ID CRD420261304804) of observational studies from PubMed, EMBASE, and Cochrane Library (inception to 19 January 2026). Pooled prevalence and odds ratios (ORs) were calculated, with subgroup analyses by region, ethnicity, and disease definition. Results: Seventy-five studies were included. The global pooled prevalence of asthma in adults with AD was 25.9% (95% CI 22.1–30.0%; I2 = 99.9%). AD was significantly associated with asthma (OR 3.64, 95% CI 2.89–4.57; I2 = 98.6%). Prevalence varied from 9.3% in Asia to 63.2% in South America. Although dupilumab and other targeted agents are effective in both diseases, isolated reports of new-onset asthma after treatment were identified; these cases more likely reflect the natural progression of AD or unmasking of pre-existing asthma than a direct adverse drug reaction. Conclusions: Asthma is highly prevalent in adults with AD and is strongly associated with AD. Geographic and ethnic disparities call for stratified screening. Clinicians should be aware that new-onset respiratory symptoms during targeted therapy may represent AD-related comorbidity rather than drug-induced asthma.
- 24 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1149
Open AccessGlobal Prevalence of Asthma in Adults with Atopic Dermatitis and the Atopic Dermatitis–Asthma Association
Background: Atopic dermatitis (AD) and asthma are common type 2 inflammatory diseases linked by the atopic march. In adults with AD, the prevalence of comorbid asthma and the strength of the AD–asthma association remain uncertain, with marked heterogeneity across studies. Moreover, the role of modern systemic therapies in this comorbidity is increasingly debated. Objective: To estimate the global pooled prevalence of asthma in adults with AD, quantify the AD–asthma association, and discuss the potential impact of targeted therapies (dupilumab, abrocitinib, omalizumab) on asthma comorbidity. Methods: Systematic review and random-effects meta-analysis (ID CRD420261304804) of observational studies from PubMed, EMBASE, and Cochrane Library (inception to 19 January 2026). Pooled prevalence and odds ratios (ORs) were calculated, with subgroup analyses by region, ethnicity, and disease definition. Results: Seventy-five studies were included. The global pooled prevalence of asthma in adults with AD was 25.9% (95% CI 22.1–30.0%; I2 = 99.9%). AD was significantly associated with asthma (OR 3.64, 95% CI 2.89–4.57; I2 = 98.6%). Prevalence varied from 9.3% in Asia to 63.2% in South America. Although dupilumab and other targeted agents are effective in both diseases, isolated reports of new-onset asthma after treatment were identified; these cases more likely reflect the natural progression of AD or unmasking of pre-existing asthma than a direct adverse drug reaction. Conclusions: Asthma is highly prevalent in adults with AD and is strongly associated with AD. Geographic and ethnic disparities call for stratified screening. Clinicians should be aware that new-onset respiratory symptoms during targeted therapy may represent AD-related comorbidity rather than drug-induced asthma.